Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.79 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | CNR2 | P34972 | 3/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870502 | 0.89 | EPHX2 (1.00) | EPHX2FAAHCNR2LTA4H | |
| SCHEMBL14162092 | 0.88 | EPHX2 (0.62) | EPHX2FAAHCNR2PDK1PDK2 | |
| SCHEMBL4878688 | 0.85 | EPHX2 (0.78) | EPHX2FAAHCNR2PDK1PDK2 | |
| SCHEMBL4879943 | 0.81 | EPHX2 (0.78) | EPHX2FAAHCNR2PDK1PDK2 | |
| SCHEMBL4880384 | 0.81 | EPHX2 (0.78) | EPHX2FAAHCNR2PDK1PDK2 | |
| SCHEMBL4255244 | 0.81 | EPHX2 (0.73) | EPHX2FAAHCNR2 | |
| SCHEMBL4882497 | 0.79 | EPHX2 (0.81) | EPHX2FAAHCNR2 | |
| SCHEMBL4875906 | 0.78 | EPHX2 (0.81) | EPHX2FAAHCNR2LTA4H | |
| SCHEMBL4877195 | 0.78 | EPHX2 (1.00) | EPHX2FAAHCNR2 | |
| SCHEMBL3999277 | 0.77 | F10 (0.50) | EPHX2PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 4/4885CNR2 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.